x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Beyond Biotech - the podcast from Labiotech

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what"s happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.

news tech news

All Episodes

31:10

Diagonal Therapeutics’ innovative clustering...

Beyond Biotech - the podcast from Labiotech ·

2026/04/24

Today we’re joined by Patrick Andre, Chief Scientific Officer at Diagonal Therapeutics. A trained vascular biologist, Patrick’s career spans groundbreaking work at Pfizer, Acceleron, Pliant Therapeutics, and earlier companies, where he focused on TGF-β superfamily signaling and receptor pathways that keep blood vessels healthy. Now at Diagonal, he’s leading a bold mission: developing clustering antibodies that correct the root cause of serious genetic vasculopathies, rather than just managing...

en-us

42:00

Argobio: the venture model building Europe’s next...

Beyond Biotech - the podcast from Labiotech ·

2026/04/17

Our guest today is Thierry Laugel, Managing Partner of Kurma & Chairman of Argobio. With a PharmD, PhD in pharmacology, and an INSEAD MBA, Thierry has spent more than two decades bridging cutting-edge science and commercial success—first in pharma R&D, then as co-founder of Kurma Partners, and now leading Argobio’s unique venture-builder model. Since raising €50 million in 2021, Argobio has co-founded and accelerated several companies from top European academic labs. Three of them—Eno...

en-us

43:42

Multi-agent AI delivers reliable and scalable...

Beyond Biotech - the podcast from Labiotech ·

2026/04/10

Today, we're exploring the transformative potential of AI in biopharma—separating hype from reality, and zooming in on the complexities of single-cell omics data. Our guest is Parashar Dhapola, co-founder and CEO of Nygen Analytics, a Lund-based startup spun out from Sweden's vibrant single-cell genomics ecosystem. With a PhD in computational genomics from Lund University, Parashar has pioneered efficient algorithms for analyzing millions of cells, turning raw data into actionable insights fo...

en-us

28:35

Nionyx Bio's kidney gene therapy wins the 2026...

Beyond Biotech - the podcast from Labiotech ·

2026/04/02

This week we welcome Magdalena Tyrpien, CEO, Co-Founder and President of Nionyx Bio, just days after the company took first place in the BIO-Europe Spring Startup Spotlight competition in Lisbon. With a background that includes leading Forge Biologics through its $620 million acquisition, Magdalena is now steering Nionyx toward a bold new chapter in gene therapy for kidney disease. In this episode we explore her journey into biotech, the science behind Nionyx’s proprietary AAV capsid platform...

en-us

43:13

HaemaLogiX - precision immunotherapy for multiple...

Beyond Biotech - the podcast from Labiotech ·

2026/03/27

Today, we welcome Dr Rosanne Dunn, Chief Scientific Officer and co-founder of HaemaLogiX, an Australian clinical-stage biotech company that's developing next-generation immunotherapies for multiple myeloma and other plasma cell disorders. HaemaLogiX is taking a precision approach by targeting novel antigens that are expressed exclusively on malignant plasma cells, sparing healthy ones. Recent peer-reviewed research has validated KMA and LMA as high-value targets, reinforcing the company's uni...

en-us

32:30

How Leyden Labs is revolutionizing flu protection...

Beyond Biotech - the podcast from Labiotech ·

2026/03/20

Today we welcome Koenraad Wiedhaup, Co-Founder and CEO of Leyden Labs, and Clarissa Koch, the company's Chief Scientific Officer. Leyden Labs is pioneering a revolutionary non-vaccine approach to combat respiratory viruses like influenza and coronaviruses. Recently, they published groundbreaking data in Science Translational Medicine, demonstrating that their intranasal antibody spray is safe, well-tolerated, and delivers sustained protection right at the virus's entry point: the nose. This i...

en-us

42:23

How to optimize your biotech company for partnering,...

Beyond Biotech - the podcast from Labiotech ·

2026/03/13

Today, we welcome Janita Good, a Partner at Fieldfisher with nearly two decades of experience advising top organizations in pharmaceuticals, biotechnology, and medical devices. With a D.Phil. in Biochemistry from the University of Oxford, Janita brings a unique blend of scientific insight and legal expertise to her work on venture investments, joint ventures, partnerships, and M&A deals. She's advised on landmark transactions, including funding rounds for Phynova and MedAnnex, and collabo...

en-us

34:14

Reversing tumor immunosuppression with next-gen GPCR...

Beyond Biotech - the podcast from Labiotech ·

2026/03/06

Today we’re joined by Sean MacDonald, CEO of Kainova Therapeutics. With more than twenty years of biotech leadership and deep expertise in strategy and development, Sean is guiding the company through an exciting new chapter. We’ll dive into Kainova’s innovative GPCR-modulating platform, its promising pipeline, the science behind reversing tumor immunosuppression and targeting inflammation, and the reasons behind the recent rebrand from Domain Therapeutics to Kainova Therapeutics. We’ll also ...

en-us

50:03

Misinformation is a public health crisis - here's how...

Beyond Biotech - the podcast from Labiotech ·

2026/02/27

Our guest is Sergey Jakimov, the Founding and Managing Partner of LongeVC, a venture capital firm dedicated to backing early-stage biotech and longevity startups. A serial entrepreneur, Sergey has co-founded ventures like Longenesis, a medical tech startup unlocking biomedical data for drug discovery, and the Longevity Science Foundation, a non-profit advancing healthy human lifespan. He’s been named to Forbes Latvia's 30 Under 30 in technology and healthcare, and via LongeVC, he invests in i...

en-us

48:53

Accelerating rare disease cures with ASOs, gene...

Beyond Biotech - the podcast from Labiotech ·

2026/02/20

Today, we're joined by Professor Matthew Wood, a leading figure in neuroscience and RNA-based therapeutics. He is Professor of Neuroscience at the University of Oxford, Deputy Head of the Medical Sciences Division, and Director of both the MDUK Oxford Neuromuscular Centre and the Oxford-Harrington Rare Disease Centre, a groundbreaking partnership between the University of Oxford and Harrington Discovery Institute dedicated to accelerating therapies for rare genetic diseases affecting millions...

en-us

32:58

Using AI to crack undruggable drug targets

Beyond Biotech - the podcast from Labiotech ·

2026/02/13

As we mark the International Day of Women and Girls in Science, we welcome Avital Sharir-Ivry, Co-Founder and Chief Scientific Officer of ProPhet, an innovative Israeli startup launched in late 2024 from the AION Labs venture studio. With a PhD in computational biology and drug research, Avital brings deep expertise in structural biology, enzyme design, and evolutionary bioinformatics to her role leading ProPhet's scientific efforts. ProPhet itself is changing small molecule drug discovery by...

en-us

35:46

How Eli Lilly's biotech collaboration model is...

Beyond Biotech - the podcast from Labiotech ·

2026/02/06

Today, we're joined by Thomas Hopkins, Vice President and Head of ExploR&D at Eli Lilly. With a background as a physician-scientist in oncology, Thomas has spent his career bridging bold discovery science with rigorous development, first in academia and clinical practice, then at Lilly since 2015. Lilly ExploR&D represents new thinking in the pharma-biotech collaboration model: a shared-risk, deep scientific partnership designed specifically for early-stage biotechs. It provides full-...

en-us

34:42

Building a smart oncology pipeline with Cumulus Oncology

Beyond Biotech - the podcast from Labiotech ·

2026/01/30

Today, my guest is Dr. Clare Wareing, Founder and CEO of Cumulus Oncology, who joins us from Edinburgh. With over 25 years of expertise in oncology drug development, Clare has built a remarkable career translating scientific breakthroughs into life-changing therapies. Cumulus Oncology is curating a risk-adjusted portfolio of preclinical assets focused on high unmet needs in oncology. Their platform-agnostic, approach prioritizes patient subgroups and precision medicine to boost success ...

en-us

36:25

Top 5 trends that will drive biopharma in the next...

Beyond Biotech - the podcast from Labiotech ·

2026/01/23

Today, we're thrilled to have Tim Opler, a leading voice in biotech investment banking. Tim's career spans academia, Credit Suisse, and co-founding Torreya Partners, which Stifel acquired in 2023. As Managing Director in Stifel's Global Healthcare Group, he's advised on over 150 deals totaling more than $100 billion, shaping major M&A, licensing, and financings in life sciences. Tim is renowned for his insightful Biopharma Market Updates, and in this episode, we'll dive into his December ...

en-us

41:28

Labiotech's 15 biopharma companies to watch in 2026

Beyond Biotech - the podcast from Labiotech ·

2026/01/16

Today I’m joined by not one, not two, but three guests with their takes on the biotech year ahead. In December we tasked Labiotech journalists Jules Adam, Roohi Peter, and Willow Shah-Neville with the task of identifying the five biotech players that they thought would be the ones to watch in 2026. Now you can read that article at Labiotech-dot-EU, and we’ve linked it in the show notes here in your podcast player, too, but on today’s episode I’m joined by Jules, Roohi, and Willow who explain ...

en-us

35:43

M Ventures: pharma CVC and biotech innovation in 2026

Beyond Biotech - the podcast from Labiotech ·

2026/01/09

Welcome to our first episode for 2026. Today, we're joined by Hakan Goker, Managing Director at M Ventures, the strategic corporate venture capital arm of Merck KGaA. With over two decades in biotech investing, Hakan has driven transformative deals in oncology, autoimmune diseases, and beyond, including standout 2025 investments like FoRx Therapeutics and portfolio milestones such as Artios' FDA Fast Track designation. As we kick off 2026 at Beyond Biotech, Hakan shares insights on corp...

en-us

34:25

Johnson & Johnson’s hematology portfolio:...

Beyond Biotech - the podcast from Labiotech ·

2025/12/19

Welcome to our final episode for 2025. We’re taking a little break for the holidays but we’ll be back again on Friday 9th of January to kick off our year with the Managing Director of Merck KGaA’s M Ventures, Hakan Goker. Today, though, I’m joined by Ester in t’Groen of Johnson & Johnson. Fresh off the American Society of Hematology (ASH) Annual Meeting in Orlando, where J&J presented over 60 abstracts, Ester shares insights into the company's portfolio and the advances that the compa...

en-us

38:47

Tackling pulmonary fibrosis: Boehringer Ingelheim’s...

Beyond Biotech - the podcast from Labiotech ·

2025/12/12

In this episode we sit down with Martin Beck, Senior Vice President and Head of the Inflammation Business Unit at Boehringer Ingelheim. Martin grew up just down the road from the company’s headquarters in Germany, joined as a scholarship student more than 20 years ago, and never really left – and you’ll hear why he still loves it. We spend most of the episode focused on a disease that doesn’t get nearly enough attention: idiopathic and progressive pulmonary fibrosis. These are rare, fatal lun...

en-us

29:47

Cracking Cancer’s Code: Transforming Research with...

Beyond Biotech - the podcast from Labiotech ·

2025/12/05

Cancer is one of the biggest health challenges worldwide. While progress has been made, millions of patients are still in need of new treatment options that better address the complexities of their disease. BeOne Medicines is creating the world’s next-generation cancer treatments with relentless innovation, aiming to deliver therapies to more people around the globe. This week, I'm sitting down with Mark Lanasa, Senior Vice President and Chief Medical Officer, Solid Tumors, at BeOne Medicines...

en-us

39:42

Curing cancer: Daiichi Sankyo's ambitious ADC approach

Beyond Biotech - the podcast from Labiotech ·

2025/11/28

Daiichi Sankyo has been pioneering ADCs since 2010, with a pipeline targeting over 30 indications and potentially reaching 400,000 patients. In today’s episode I’m joined by Dr. Markus Kosch, Head of the EU Oncology Business Division at Daiichi Sankyo. A physician by training with a deep academic background in oncology, Markus has spent over two decades advancing cancer care, from clinical practice to leadership roles shaping strategy across Europe and Canada. Since joining Daiichi Sankyo in ...

en-us

194 results

Similar Podcasts

Expres Ráno

Expres FM

PBS News Hour - Full Show

PBS News

CD Voice

China Daily

Israel Today: Ongoing War Report

Noa Levi

Jeffrey Epstein: The Coverup Chronicles

Bobby Capucci